A Repeat Positive C. auris Test After Treatment Represents True Persistent Colonization or Recolonization, Not Dormancy
In patients previously treated for Candida auris who test positive again, this represents true persistent colonization or recolonization rather than dormant fungus reactivating—C. auris does not have a dormant state but rather exhibits prolonged skin persistence that can last months. 1, 2
Understanding C. auris Persistence vs. Dormancy
C. auris fundamentally differs from other Candida species through its unique capacity for persistent skin colonization, not dormancy 3. The fungus actively colonizes skin surfaces and can persist for extended periods:
- Approximately 60% of colonized patients clear C. auris within 5 months (median time to clearance) when removed from endemic settings 2
- 40% remain persistently colonized at long-term follow-up 2
- The organism does not "lay dormant"—it actively persists on skin surfaces, particularly in the axilla and groin regions 1, 4
Clinical Interpretation of Repeat Positive Tests
When encountering a repeat positive test, consider these scenarios:
True Persistent Colonization (Most Common)
- The patient never fully cleared the organism after initial treatment
- Risk factors for persistent colonization include: 2
- Lower functional status (Karnofsky Performance Status Score)
- Prolonged antibiotic exposure
- Prolonged antifungal therapy (paradoxically)
- Previous C. auris candidemia treatment
Recolonization from Environmental Sources
- Re-exposure in healthcare settings where C. auris circulates
- A single negative screening swab is insufficient to exclude colonization 4
- Even swabs performed within 24 hours before transfer can be followed by positive results 4
Critical Screening Recommendations
To definitively establish loss of colonization, guidelines require 3 consecutive negative composite axilla/groin swabs taken at least 24 hours apart 1. This is essential because:
- Single negative tests have poor negative predictive value 4
- Among patients with negative swabs within 1 day before transfer, 7.1% subsequently tested positive 4
- 61.8% of newly detected colonization appears on the first post-transfer swab, but others emerge later 4
Distinguishing Colonization from Infection
Your repeat positive test requires clinical context to determine significance:
Colonization (More Common - 60.5% of cases) 5
- Positive screening swabs (axilla/groin) without clinical signs
- Isolation from non-sterile sites (urine, sputum, catheters) without systemic symptoms
- No treatment required for colonization alone
True Infection (39.5% of cases) 5
- Candidemia is the predominant invasive presentation (76.5% of infections) 5
- Risk of progression: 11.8% of patients with colonization detected post-transfer developed candidemia 4
- Infected patients show longer hospitalizations (median 73 vs 57.5 days) 5
- Higher mortality in infected vs colonized patients (43.1% vs 28.2%) 5
Key Clinical Differentiators
- Pharyngeal colonization shows statistically significant association with candidemia development 6
- Central venous catheter use increases infection risk (OR 2.25) 5
- Mechanical ventilation strongly associated with candidemia (OR 9.25) 5
Practical Management Algorithm
- Obtain composite axilla/groin swabs using specialized chromogenic or salt-containing media 1
- Perform repeated screening: ideally within first 2 weeks, then weekly 4
- Assess clinical context:
- Check for fever, hemodynamic instability, or organ dysfunction
- Examine for central lines, mechanical ventilation, recent surgery
- Review functional status and recent antimicrobial exposures
- If infection suspected: obtain blood cultures (2-3 sets, 20 mL each) 1
- Maintain contact precautions until 3 consecutive negative swabs 24+ hours apart 1
Common Pitfalls to Avoid
- Do not assume a single negative test means clearance—this is the most critical error 4
- Do not interpret all positive cultures as requiring antifungal treatment—distinguish colonization from infection 7
- Do not discontinue isolation prematurely—environmental persistence drives transmission 1
- Do not overlook pharyngeal colonization—this site correlates with candidemia risk 6
Antifungal Considerations
If true infection is confirmed, note the resistance patterns:
- Universal fluconazole resistance (100%) 5, 8
- Echinocandins remain first-line with preserved activity (96.6-100% susceptibility) 5
- Echinocandin resistance can emerge during therapy 8
- Amphotericin B shows limited activity (5.2% susceptibility) 5
The bottom line: Your patient's repeat positive represents ongoing colonization that either never cleared or represents recolonization, not fungal dormancy. Determine whether this is clinically significant infection requiring treatment or asymptomatic colonization requiring only infection control measures.